Skip to content
IJPT International Journal of Pharmacology and Toxicology E-ISSN 2310-2985

Pharmacokinetics of Lornoxicam in rabbits after single intravenous bolus and intramuscular administrations

Abstract

The pharmacokinetics of lornoxicam (a non-steroidal anti-inflammatory drug) at a dose of 0.4 mg/Kg body weight was evaluated after single intravenous (i.v.) and intramuscular (i.m.) bolus administrations in rabbits. An HPLC assay using pure lornoxicam base as a standard was used to measure its concentrations in plasma at prefixed time points up to 12 hours post administration. Following an i.v. bolus injection, the plasma concentration-time curves of lornoxicam were best represented by two-compartment open model. The drug was rapidly distributed and moderately eliminated with half-lives of distribution (t1/2α) and elimination (t1/2β) of 0.238 and 2.611 h, respectively. The volume of distribution was large with (Vdss) value of 1.499 L. The total body clearance (ClB) was 0.413 L/h. After i.m. bolus administration of the same dose, lornoxicam was moderately and completely absorbed in rabbits with an absorption half-life (t½ab) of 1.228 h with peak plasma concentration (Cmax) of 0.463 μg/mL attained at 1.512 h (Tmax) and systemic bioavailability of 99.79%. The elimination half-life following i.m. administration was 2.283 h. The extent of plasma protein binding percent was 98.9%. The study recommends the use of lornoxicam in rabbits because of its good pharmacokinetic profile indicated by good absorption, bioavailability and plasma concentrations.

Authors and Affiliations

About this article

Download PDF

Keywords

  • Lornoxicam
  • Pharmacokinetics
  • Intravenous
  • Intramuscular
  • Rabbits.

References

[1] Baggot J 1995, Pharmacokinetics: disposition and fate of drugs in the body. Veterinary pharmacology and therapeutics 18-52.

[2] Baggot JD 1977, Principles of drug disposition in domestic animals: the basis of veterinary clinical pharmacology: WB Saunders.

[3] Baggot JD 1978a, Some aspects of clinical pharmacokinetics in veterinary medicine II. Journal of Veterinary Pharmacology and Therapeutics 1, 111-118. http://dx.doi.org/10.1111/j.1365-2885.1978.tb00314.x.

[4] Baggot JD 1978b, Some aspects of clinical pharmacokinetics in veterinary medicine. I. Journal of Veterinary Pharmacology and Therapeutics 1, 5-18. http://dx.doi.org/10.1111/j.1365-2885.1978.tb00300.x.

[5] Balfour JA, Fitton A & Barradell LB 1996, Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 51, 639-657. http://dx.doi.org/10.2165/00003495-199651040-00008.

[6] Bhandari S & Khisti N 2012, Extraction-less high-performance liquid chromatographic method for determination of lornoxicam in human plasma. Asian Journal of Pharmaceutical and Clinical Research 5, 122-124.

[7] Botting JH 1999, Nonsteroidal antiinflammatory agents. Drugs Today 35, 225. http://dx.doi.org/10.1358/dot.1999.35.4-5.552199.

[8] Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, Pick S & Trzaskos JM 1994, Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proceedings of the National Academy of Sciences 91, 11202-11206. http://dx.doi.org/10.1073/pnas.91.23.11202.

[9] Craig W & Suh B 1991, Protein binding and the antimicrobial effects: methods for the determination of protein binding. Antibiotics in laboratory medicine Williams & Wilkins, Baltimore, Md 367-402.

[10] Dorrestein GM 1991, The pharmacokinetics of avian therapeutics. Veterinary Clinics of North America: Small Animal Practice 21, 1241-1264. http://dx.doi.org/10.1016/S0195-5616(91)50135-2.

[11] El Dareer SM, Noker PE & and Galbraith WM 1990, Disposition of [14C] lornoxicam in male and female cynomolgus monkeys dosed orally or intravenously. The FASEB Journal 4, A461 (Abstr. 1132).

[12] Grizzle JE 1965, The two-period change-over design and its use in clinical trials. Biometrics 467-480. http://dx.doi.org/10.2307/2528104.

[13] Heeb H, Chun R, Koch D, Goatley M & Hunter R 2003, Single dose pharmacokinetics of piroxicam in cats. Journal of Veterinary Pharmacology and Therapeutics 26, 259-263. http://dx.doi.org/10.1046/j.1365-2885.2003.00479.x.

[14] Heintz R, Guentert T, Enrico J, Dubach U, Brandt R & Jeunet F 1983, Pharmacokinetics of tenoxicam in healthy human volunteers. European Journal of Rheumatology and Inflammation 7, 33-44.

[15] Hitzenberger G, Radhofer-Welte S, Takacs F & Rosenow D 1989, Pharmacokinetics of lornoxicam in man. Postgraduate Medical Journal 66, S22-27.

[16] Kölle E & Vollmer K-O 1986, Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers. British Journal of Clinical Pharmacology 22, 135S. http://dx.doi.org/10.1111/j.1365-2125.1986.tb02995.x.

[17] Liang Y, Shi Q & Zhou Y-w 2006, Pharmacokinetics and bioequivalence of lornoxicam tablet in healthy volunteers. Chinese Journal of Clinical Pharmacology 22, 336.

[18] Lirk P, Seymour R-A, Ong C-K-S & Tan C-H 2007, An evidence-based update on nonsteroidal anti-Inflammatory Drugs. Clin Med Res 5, 19-34. http://dx.doi.org/10.3121/cmr.2007.698.

[19] Merck-Veterinary-Manual 2016, Nonsteroidal antiinflammatory drugs. Available at http://www.merckvetmanual.com/mvm/pharmacology/anti-inflammatory_agents/nonsteroidal_anti-inflammatory_drugs.html.

[20] Pabst G & Jaeger H 1990, Review of methods and criteria for the evaluation of bioequivalence studies. European Journal of Clinical Pharmacology 38, 5-10. http://dx.doi.org/10.1007/BF00314794.

[21] Paget G & Barnes J 1964, Toxicity tests. Evaluation of drug activities: Pharmacometrics 1, 135.

[22] Prasad Byrav D, Medhi B, Prakash A, Patyar S & Wadhwa S 2009, Lornoxicam: a newer NSAID. IJPMR 20, 27-31.

[23] Radhofer-Welte S & Rabasseda X 2000, Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today 36, 55-76. http://dx.doi.org/10.1358/dot.2000.36.1.566627.

[24] Riegelman S, Loo J & Rowland M 1968, Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. Journal of Pharmaceutical Sciences 57, 117-123. http://dx.doi.org/10.1002/jps.2600570123.

[25] Riggs DS 1964, The Mathematical Approach to Physiological Problems. Academic Medicine 39, 235.

[26] Rosenbaum SE 2012, Basic pharmacokinetics and pharmacodynamics: An integrated textbook and computer simulations: John Wiley & Sons.

[27] SPSS IBM 2011, Version 20. New York, NY, USA: IBM Incorporation.

[28] Watkins J & Klaassen CD 1986, Xenobiotic biotransformation in livestock: comparison to other species commonly used in toxicity testing. Journal of Animal Science 63, 933-942.

[29] Zhang Y, Zhong D, Si D, Guo Y, Chen X & Zhou H 2005, Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. British Journal of Clinical Pharmacology 59, 14-17. http://dx.doi.org/10.1111/j.1365-2125.2005.02223.x.


How to Cite

El-Mahmoudy, A. (2016). Pharmacokinetics of Lornoxicam in rabbits after single intravenous bolus and intramuscular administrations. International Journal of Pharmacology and Toxicology, 4(1), 66-73. https://doi.org/10.14419/ijpt.v4i1.5998